Analyst Price Targets — IRMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 11, 2026 1:44 pm | — | Lake Street | $120.00 | $106.02 | TheFly | iRadimed price target raised to $120 from $100 at Lake Street |
| February 10, 2026 8:36 pm | — | Roth Capital | $120.00 | $105.15 | TheFly | iRadimed price target raised to $120 from $98 at Roth Capital |
| November 3, 2025 8:10 pm | Kyle Bauser | Roth Capital | $98.00 | $84.11 | TheFly | iRadimed price target raised to $98 from $90 at Roth Capital |
| November 3, 2025 6:28 pm | — | Lake Street | $100.00 | $84.11 | TheFly | iRadimed price target raised to $100 from $75 at Lake Street |
| October 31, 2025 8:24 am | Kyle Bauser | Roth Capital | $90.00 | $76.42 | TheFly | iRadimed resumed with a Buy at Roth Capital |
| August 2, 2024 8:40 am | Jason Wittes | Roth Capital | $60.00 | $46.15 | TheFly | iRadimed price target lowered to $60 from $65 at Roth MKM |
| June 17, 2024 9:49 am | Frank Takkinen | Loop Capital Markets | $60.00 | $43.29 | StreetInsider | Lake Street Capital Markets Reiterates Buy Rating on IRadimed Corp (IRMD) |
Latest News for IRMD
Algert Global LLC trimmed its stake in iRadimed Corporation (NASDAQ: IRMD) by 17.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,994 shares of the medical equipment provider's stock after selling 15,062 shares during the period. Algert Global
Shares of iRadimed Corporation (NASDAQ: IRMD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five ratings firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong
iRadimed NASDAQ: IRMD reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, as the company began general-release production of its new 3870 MRI IV pump system and worked through the costs associated with an initial manufacturing ramp.
IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $20.5 million for the second quarter of 2026, which increased by $0.1 million, or 0.5% compared to the same period in 2025. Reports GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46 for the second quarter of 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IRMD.
U.S. House Trading
No House trades found for IRMD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.